Αρχική World News Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among... World News Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma Από Ogkologos - 2 Ιουλίου, 2026 214 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... 13 Νοεμβρίου, 2020 Managing Side Effects with South Asian Foods 19 Ιουλίου, 2022 GPRC5D Is An Active Immunotherapeutic Target in Multiple Myeloma 5 Οκτωβρίου, 2022 PDX Mouse Models Are Reliable Stand-Ins for Human Tumors, Study Finds 2 Φεβρουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom... Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or...